CHIR-090 is primarily utilized in biochemical research as a potent and selective inhibitor of LpxC, an enzyme critical for the biosynthesis of lipid A in Gram-negative bacteria. Its application is significant in studying bacterial resistance mechanisms and developing novel antibiotics. Researchers employ CHIR-090 to explore its potential in combating infections caused by multidrug-resistant pathogens, particularly Pseudomonas aeruginosa. Additionally, it serves as a valuable tool in understanding the role of lipid A in bacterial cell wall integrity and immune system evasion. Its use extends to preclinical studies aimed at identifying new therapeutic strategies for treating severe Gram-negative bacterial infections.